Summary
Digital displays are ubiquitous in modern daily life. In many areas, such displays have replaced, or are in the process of replacing, conventional items such hard-copy books, analogue watches and car dashboard gauges. Similarly, many clinical vision tests are increasingly being presented on a range of modern visual displays ranging from LCD monitors to OLED displays for use in the home and clinical settings; a move away from antiquated (but still regularly used) non-digital systems. Measurements obtained from these devices are relied upon by clinicians to make decisions about patient wellbeing and treatment, and therefore need to be fit-for-purpose to meet the challenges of modern-day clinical practice. Despite the positive move to more modern platforms, it is still imperative that legacy measures, often collected over decades, can be incorporated into the determination of disease stability or otherwise. Thus, there is a need to ensure that the benefits of novel platforms ar
Summary
The prevalence of type 2 diabetes has risen dramatically during recent decades and there is an urgent need to develop new approaches for therapeutic treatment that provide a combination of benefits, with fewer side effects and better patient outcomes. When diabetes is not managed, it can lead to serious complications including cardiovascular disease (CVD), stroke, blindness, kidney disease and premature mortality. CVD is a major cause of death and disability in diabetes, accounting for 52% of fatalities in those with type 2 diabetes.
New treatments are necessary due to the increasing prevalence of diabetes and its complications. In recent years, therapies that target the actions of glucagon-like peptide-1 (GLP-1) which stimulate insulin secretion through activation of beta cell G protein-coupled receptors (GPCRs) have been successful. This has resulted in substantial interest in targeting other islet GPCRs for diabetic therapies [1-3]. GPCRs are a superfamily of transmembra